Pilot study of dovitinib in patients with von Hippel-Lindau disease

Von Hippel-Lindau (VHL) disease is an autosomal dominant disease occurring in 1 in 35,000 births and leads to an increased risk of a phenotypically diverse array of tumor types including, but not limited to, clear cell renal cell carcinoma (ccRCC) and hemangioblastomas (HBs). Previous studies of pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Pilié, Patrick, Hasanov, Elshad, Matin, Surena F., Woodson, Ashley H. Henriksen, Marcott, Valerie D., Bird, Shelly, Slack, Rebecca S., Fuller, Gregory N., McCutcheon, Ian E., Jonasch, Eric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5955100/
https://www.ncbi.nlm.nih.gov/pubmed/29805741
http://dx.doi.org/10.18632/oncotarget.25171

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5955100/
https://www.ncbi.nlm.nih.gov/pubmed/29805741
http://dx.doi.org/10.18632/oncotarget.25171

Ejemplares similares